Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    23200175 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Not yet recruiting A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung
Condition: Carcinoma of the Lung.
Interventions: Drug: Binimetinib;   Drug: Pemetrexed;   Drug: Carboplatin
2 Active, not recruiting Comparison of AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive Non Small Cell Lung Cancer (NSCLC) Patients
Condition: Non Small Cell Lung Cancer
Interventions: Drug: AZD6244;   Drug: docetaxel;   Drug: Placebo

Indicates status has not been verified in more than two years